Re: Promissory Note dated May 19, 2006 (the “Note”)Promissory Note Conversion Agreement • March 4th, 2013 • Cancer Genetics, Inc • Services-medical laboratories
This letter agreement will memorialize your agreement with respect to $100,000 of the outstanding principal amount of your loan to Cancer Genetics, Inc., a Delaware corporation (the “Company”), made pursuant to the Note, plus all accrued and unpaid interest thereon (such accrued and unpaid interest plus the outstanding principal amount, the “Conversion Amount”). The promises set forth in this letter agreement are made to induce us and our underwriters to proceed with the initial public offering, which is also beneficial to you.
Re: Warrant No. W- Dear :Warrant Amendment Agreement • March 4th, 2013 • Cancer Genetics, Inc • Services-medical laboratories
This letter agreement will memorialize your agreement with respect to certain anti-dilution provisions contained in a warrant to purchase common stock of Cancer Genetics, Inc., a Delaware corporation (the “Company”), held by you. The promises set forth in this letter agreement are made to induce us and our underwriters to proceed with the initial public offering, which is also beneficial to you.
